The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.2 - Manufacture of pharmaceutical preparations
104 - 347 jobs Number of planned job losses
Announcement Date
13 October 2023
Employment effect (start)
14 October 2023
Foreseen end date
Description
Catalent, an American multinational pharmaceutical company specialised in the development and production in cell therapy, has announced it will be reorganising its facility in Gosselies. The company management has announced it will dismiss approximately 104 of 347 employees within the facility.
The restructuring has been caused by newer regulation introduced, problems in the supply chain and the rising cost of salaries. The broader context is that the sector is currently undergoing difficulties, in addition the company is faced with the postponement of investments by customers, as well as the announcement of the end of programmes by 2 of their main customers.
Eurofound (2023), Catalent, Internal restructuring in Belgium, factsheet number 200389, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/200389.